Nisa Investment Advisors LLC Grows Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Nisa Investment Advisors LLC lifted its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 5.2% during the third quarter, HoldingsChannel.com reports. The fund owned 2,209 shares of the company’s stock after buying an additional 110 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Vaxcyte were worth $252,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the stock. Riverview Trust Co bought a new position in Vaxcyte in the third quarter worth approximately $27,000. Blue Trust Inc. grew its position in shares of Vaxcyte by 33.5% during the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after buying an additional 93 shares in the last quarter. Fifth Third Bancorp purchased a new position in shares of Vaxcyte during the second quarter valued at $35,000. Fidelis Capital Partners LLC bought a new stake in shares of Vaxcyte in the first quarter valued at about $37,000. Finally, J.Safra Asset Management Corp lifted its stake in Vaxcyte by 649.4% in the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock worth $46,000 after acquiring an additional 526 shares during the period. 96.78% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $106.80, for a total value of $854,400.00. Following the sale, the chief operating officer now owns 205,695 shares in the company, valued at approximately $21,968,226. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, CEO Grant Pickering sold 15,000 shares of the company’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $78.98, for a total value of $1,184,700.00. Following the completion of the transaction, the chief executive officer now owns 478,888 shares of the company’s stock, valued at approximately $37,822,574.24. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Jim Wassil sold 8,000 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $106.80, for a total value of $854,400.00. Following the completion of the sale, the chief operating officer now directly owns 205,695 shares in the company, valued at approximately $21,968,226. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 115,098 shares of company stock valued at $12,394,473 over the last ninety days. Company insiders own 3.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on PCVX. Bank of America raised their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Mizuho lifted their price objective on shares of Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a report on Tuesday, September 10th. Leerink Partners upped their target price on Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a report on Tuesday, September 3rd. BTIG Research lifted their price target on Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Finally, Needham & Company LLC restated a “buy” rating and set a $140.00 price objective on shares of Vaxcyte in a research note on Wednesday. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vaxcyte has a consensus rating of “Buy” and a consensus price target of $147.50.

Vaxcyte Trading Down 3.2 %

Shares of NASDAQ PCVX opened at $104.07 on Thursday. The company has a 50 day simple moving average of $110.06 and a two-hundred day simple moving average of $86.69. The stock has a market cap of $11.62 billion, a price-to-earnings ratio of -22.62 and a beta of 1.01. Vaxcyte, Inc. has a 12 month low of $46.16 and a 12 month high of $121.06.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter last year, the company earned ($0.91) EPS. Analysts forecast that Vaxcyte, Inc. will post -4.33 EPS for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.